Abeona Therapeutics (ABEO) vs Perspective Therapeutics (CATX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Abeona Therapeutics (ABEO) has outperformed Perspective Therapeutics (CATX) over the past year, losing 3.2% versus a loss of 29.1%. Over five years, CATX leads with a -60.3% price change compared with -77.7% for ABEO. Perspective Therapeutics is the larger company by market cap ($307.6 million vs $285.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | CATX |
|---|---|---|
| Share price | $4.99 | $2.70 |
| Market cap | $285.06M | $307.64M |
| 1-day change | -1.87% | +9.55% |
| YTD return | -3.61% | -10.55% |
| 1-year return | -3.24% | -29.11% |
| 5-year return | -77.67% | -60.32% |
| EPS (TTM) | $-1.18 | $-1.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.65 | $6.16 |
| 52-week low | $4.00 | $1.96 |
| Distance from 52-week high | -34.84% | -56.25% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +278.74% | +356.03% |
| Average volume | 1.41M | 1.67M |
| Shares outstanding | 57.18M | 114.15M |
| Employees | 226 | 163 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABEO has outperformed CATX by 25.9 percentage points over the past year.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
ABEO vs CATX FAQ
Which is bigger, Abeona Therapeutics or Perspective Therapeutics?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $307.64M compared with $285.06M for Abeona Therapeutics (ABEO).
Which stock has performed better over the past year, ABEO or CATX?
ABEO returned -3.24% over the past 12 months, compared with -29.11% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and Perspective Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.